COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 2 of 739 for:    Phase II astrocytoma

SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00783393
Recruitment Status : Completed
First Posted : October 31, 2008
Last Update Posted : May 15, 2017
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
The primary purpose of the study is to evaluate the efficacy (overall response) and safety of temozolomide in Step 1 at the dose and regimen approved in the US and the EU countries (28 day cycles of temozolomide at 150 to 200 mg/m2 once daily for 5 consecutive days with a 23 day rest period) in patients with anaplastic astrocytoma at first relapse.

Condition or disease Intervention/treatment Phase
Astrocytoma Drug: Temozolomide Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma
Actual Study Start Date : May 27, 2003
Actual Primary Completion Date : June 17, 2005
Actual Study Completion Date : June 17, 2005

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Single arm

The study consists of two steps:

  • Step 1, the therapeutic study phase, comprising six cycles of treatment with temozolomide, and
  • Step 2, the long-term treatment phase, where subjects with at least disease stabilization at the end of Step 1 may continue temozolomide treatment until unacceptable toxicity or disease progression occur, up to a maximum of 2 years from the start of treatment in Cycle 1.
Drug: Temozolomide
Temozolomide orally once daily for 5 consecutive days followed by a 23 day rest period to complete a 28 day treatment cycle. In Cycle 1, temozolomide will be administered at 150 mg/m2/day; in Cycle 2 and subsequent cycles, it will be administered at 100, 150, or 200 mg/m2, depending on hematology test results and adverse events observed.
Other Name: Temodal, Temodar, SCH 052365

Primary Outcome Measures :
  1. Overall response in Step 1 [ Time Frame: 6 months ]
  2. Incidence rate and severity of adverse events with administration of temozolomide in Step 1 [ Time Frame: 7 months (during temozolomide administration for 6 months and follow-up for 1 month) ]

Secondary Outcome Measures :
  1. Progression-free survival in Step 1 [ Time Frame: 6 months ]
  2. Overall survival in Step 1 [ Time Frame: 6 months ]
  3. Tumor response in Step 1 [ Time Frame: 6 months ]
  4. Neurological improvement in Step 1 [ Time Frame: 6 months ]
  5. Progression-free survival, overall survival, overall response, effect on neurological symptoms, and safety in Step 2 [ Time Frame: 6 months ]
  6. Progression-free survival in Step 2 [ Time Frame: Up to 2 years ]
  7. Overall survival in Step 2 [ Time Frame: Up to 2 years ]
  8. Overall response in Step 2 [ Time Frame: Up to 2 years ]
  9. Effect on neurological symptoms in Step 2 [ Time Frame: Up to 2 years ]
  10. Safety in Step 2 [ Time Frame: Up to 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject must have histologically confirmed anaplastic astrocytoma on the tentorium at first relapse, and satisfy the following:

    • unequivocal evidence of tumor recurrence or aggravation by MRI scan after treatment for initial onset; the lesions must be measurable;
    • anaplastic astrocytoma diagnosed histologically by the last pathological diagnostic tests (including initial diagnosis) prior to initial administration of temozolomide;
    • tissue samples available for Central Pathologic Reviewer;
    • pathologic diagnosis report by the study-conducting medical institution must be available for the sponsor.
  • MRI-related criteria:

    • MRI scan performed within 14 days before initial temozolomide administration;
    • assessable tumor site confirmed by MRI;
    • dosage of steroidal agents not increased within 7 days before MRI prior to initial temozolomide administration, except for postoperative subjects for first relapse;
    • MRI performed at the Principal Investigator's study location or designated radiology facility during the study.
  • Age >=18 years, either sex, inpatients or outpatients.
  • Use of medically approved contraception methods in fertile subjects.
  • Karnofsky performance status >=70.
  • Adequate clinically laboratory values obtained within 14 days before initial temozolomide administration.
  • Criteria regarding treatment of initial onset:

    • tumor biopsy, regardless of tumor resection at initial diagnosis;
    • prior radiation therapy;
    • prior chemotherapy with up to one nitrosourea-containing regimen.
  • Tumor may or may not have been surgically resected at first relapse, but residual measurable disease is required.
  • For subjects who had surgical resection of tumor at first relapse:

    • MRI scan must have been performed within 72 hours after surgery.
    • the dose of steroidal agents must be reduced before temozolomide administration.
  • Life expectancy >=12 weeks.
  • Written informed consent obtained.

Exclusion Criteria:

  • History of treatment with dacarbazine.
  • Subjects who received chemotherapy within 6 weeks before initial temozolomide administration.
  • Subjects who received interstitial radiotherapy or stereotactic radiosurgery.
  • Subjects who completed radiotherapy within 12 weeks before initial temozolomide administration.
  • Surgery at first relapse (including biopsy) within 1 week before initial temozolomide administration.
  • Subjects not recovered from acute toxicity due to previous therapy.
  • High-risk subjects with complication of diseases other than malignant tumor, or who require systemic administration of antibiotics for infection.
  • Previous or concurrent malignancies at other sites.
  • Pregnant or nursing women.
  • Women of childbearing potential not using an effective method of contraception.
  • Subjects previously treated with temozolomide.
  • Participation in an ongoing clinical study, or in other clinical studies within 6 months before initial temozolomide administration.
  • Subjects found inappropriate for the study by the investigator or subinvestigator.

Study Data/Documents: CSR Synopsis  This link exits the site

Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00783393    
Other Study ID Numbers: P03745
First Posted: October 31, 2008    Key Record Dates
Last Update Posted: May 15, 2017
Last Verified: May 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents